This is a preview of subscription content, log in to check access.
Hall KH, et al. New and Worsening Long-term, Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer. Pharmacotherapy : 12 Dec 2019. Available from: URL: http://doi.org/10.1002/phar.2354
About this article
Cite this article
Long-term PD-1/PD-L1 inhibitor therapy leads to late irAEs. Reactions Weekly 1786, 9 (2020). https://doi.org/10.1007/s40278-020-73483-0